Original Article

You have full text access to this OnlineOpen article

Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer†

Findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study

  1. Nadine A. Jackson MD, MPH1,
  2. José Barrueco PhD2,
  3. Raoudha Soufi-Mahjoubi MD2,
  4. John Marshall MD3,
  5. Edith Mitchell MD4,
  6. Xiaoxi Zhang PhD2,
  7. Jeffrey Meyerhardt MD, MPH1,‡,*

Article first published online: 20 APR 2009

DOI: 10.1002/cncr.24305

Issue

Cancer

Cancer

Volume 115, Issue 12, pages 2617–2629, 15 June 2009

Additional Information

How to Cite

Jackson, N. A., Barrueco, J., Soufi-Mahjoubi, R., Marshall, J., Mitchell, E., Zhang, X. and Meyerhardt, J. (2009), Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer. Cancer, 115: 2617–2629. doi: 10.1002/cncr.24305

Author Information

  1. 1

    Department of Gastrointestinal Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

  2. 2

    Pfizer Global Pharmaceuticals, New York, New York

  3. 3

    Department of Medical Oncology, Georgetown University Lombardi Cancer Center, Washington, District of Columbia

  4. 4

    Department of Medical Oncology, Jefferson Medical College, Philadelphia, Pennsylvania

  1. ‡

    Fax: (617) 632-5370

*44 Binney Street, Boston, MA 02115

  1. †

    Presented in part at the 43rd Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, June 1-5, 2007.

Publication History

  1. Issue published online: 4 JUN 2009
  2. Article first published online: 20 APR 2009
  3. Manuscript Accepted: 8 DEC 2008
  4. Manuscript Revised: 19 NOV 2008
  5. Manuscript Received: 10 SEP 2008

Funded by

  • Pfizer Inc, New York

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (344K)

References

  • 1
    National Institutes of Health. Surveillance Epidemiology and End Results. Available at: http://seer.cancer.gov/ Accessed on January 23, 2008.
  • 2
    Parkin DM,Bray F,Ferlay J,Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.
    Direct Link:
  • 3
    United States Census Bureau. Population Projections of the United States, by Age, Race, and Hispanic Origin, 1993-2050, 1993. Available at: http://www.census.gov. Accessed on January 23, 2008.
  • 4
    Rosati G. Elderly patients with advanced colorectal cancer: which therapy is the safest? Expert Opin Drug Saf. 2005; 4: 1041-1049.
  • 5
    Walter LC,Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA. 2001; 285: 2750-2756.
  • 6
    Grothey A,Sargent D,Goldberg RM,Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004; 22: 1209-1214.
  • 7
    Goldberg RM,Tabah-Fisch I,Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006; 24: 4085-4091.
  • 8
    Berardi R,Saladino T,Mari D, et al. Elderly patients with advanced colorectal cancer: tolerability and activity of chemotherapy. Tumori. 2005; 91: 463-466.
  • 9
    Dranitsaris G,Shah A,Spirovski B,Vincent M. Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool. Clin Colorectal Cancer. 2007; 6: 367-373.
  • 10
    Emmanouilides C,Sfakiotaki G,Androulakis N, et al. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer. 2007; 7: 91.
  • 11
    Figer A,Perez-Staub N,Carola E, et al. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer. 2007; 110: 2666-2671.
    Direct Link:
  • 12
    Kim JH,Oh DY,Kim YJ, et al. Reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer. J Korean Med Sci. 2005; 20: 806-810.
  • 13
    Nardi M,Azzarello D,Maisano R, et al. FOLFOX-4 regimen as fist-line chemotherapy in elderly patients with advanced gastric cancer: a safety study. J Chemother. 2007; 19: 85-89.
  • 14
    Souglakos J,Pallis A,Kakolyris S, et al. Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. Oncology. 2005; 69: 384-390.
  • 15
    Goldberg RM,Sargent DJ,Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004; 22: 23-30.
  • 16
    Folprecht G,Seymour MT,Saltz L, et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol. 2008; 26: 1443-1451.
  • 17
    Tournigand C,Andre T,Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22: 229-237.
  • 18
    Aparicio J,Fernandez-Martos C,Vincent JM, et al. FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer. 2005; 5: 263-267.
  • 19
    Colucci G,Gebbia V,Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol. 2005; 23: 4866-4875.
  • 20
    Golfinopoulos V,Salanti G,Pavlidis N,Ioannidis JP. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol. 2007; 8: 898-911.
  • 21
    Kalofonos HP,Aravantinos G,Kosmidis P, et al. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Ann Oncol. 2005; 16: 869-877.
  • 22
    Matasar MJ,Sundararajan V,Grann VR,Neugut AI. Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy. Drugs Aging. 2004; 21: 113-133.
  • 23
    Ragnhammar P,Hafstrom L,Nygren P,Glimelius B. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol. 2001; 40: 282-308.
  • 24
    Fuchs CS,Marshall J,Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007; 25: 4779-4786.
  • 25
    Solomon SD,McMurray JJ,Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005; 352: 1071-1080.
  • 26
    Camptosar [package insert]. New York, NY: Pfizer Oncology; 2006.
  • 27
    Therasse P,Arbuck SG,Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
  • 28
    Cox D. Regression models and life-tables. J R Stat Soc. 1972; 34: 187-220.
  • 29
    Chau I,Norman AR,Cunningham D, et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Ann Oncol. 2005; 16: 549-557.
  • 30
    Cunningham D,Pyrhoenen S,James R, et al. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998; 352: 1413-1418.
  • 31
    Fuchs C,Moore M,Harker G,Villa L,Rinaldi D,Hecht J. Phase III comparison of 2 irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol. 2003; 21: 807-814.
  • 32
    Schaaf L,Ichhpurani N,Elfring G,Wolf M,Rothenberg M,Von Hoff D. Influence of age on the pharmacokinetics of irinotecan (CPT-11) and its metabolites, SN-38 and SN-38 glucuronide (SN-38G), in patients with previously treated colorectal cancer. Proc Am Soc Clin Oncol. 1997; 16: A708.
  • 33
    Rothenberg ML,Cox JV,DeVore RF, et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer. 1999; 85: 786-795.
    Direct Link:
  • 34
    Mitry E,Phelip J,Bonnetain F, et al. Phase III trial of chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients (FFCD 2001-02 trial): results of a planned interim analysis. 9th Meeting of the Society of International Geriatric Oncology Meeting. Critical Reviews in Oncology/Hematology. 2008;68:S23.
  • 35
    Kabbinavar FF,Hambleton J,Mass RD,Hurwitz HI,Bergsland E,Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005; 23: 3706-3712.
  • 36
    Falcone A,Ricci S,Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007; 25: 1670-1676.
  • 37
    Souglakos J,Androulakis N,Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006; 94: 798-805.
  • 38
    Teufel A,Steinmann S,Siebler J, et al. Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. BMC Cancer. 2004; 4: 38.
  • 39
    Balducci L,Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000; 5: 224-237.
  • 40
    Hutchins LF,Unger JM,Crowley JJ,Coltman CAJr,Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999; 341: 2061-2067.
  • 41
    Mahoney T,Kuo YH,Topilow A,Davis JM. Stage III colon cancers: why adjuvant chemotherapy is not offered to elderly patients. Arch Surg. 2000; 135: 182-185.
  • 42
    Mor V,Masterson-Allen S,Goldberg RJ,Cummings FJ,Glicksman AS,Fretwell MD. Relationship between age at diagnosis and treatments received by cancer patients. J Am Geriatr Soc. 1985; 33: 585-589.
  • 43
    Sanoff HK,Bleiberg H,Goldberg RM. Managing older patients with colorectal cancer. J Clin Oncol. 2007; 25: 1891-1897.
  • 44
    Ford JG,Howerton MW,Lai GY, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer. 2008; 112: 228-242.
    Direct Link:
  • 45
    Howerton MW,Gibbons MC,Baffi CR, et al. Provider roles in the recruitment of underrepresented populations to cancer clinical trials. Cancer. 2007; 109: 465-476.
    Direct Link:
  • 46
    Kornblith AB,Kemeny M,Peterson BL, et al. Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer. 2002; 95: 989-996.
    Direct Link:
  • 47
    Kumar A,Soares HP,Balducci L,Djulbegovic B. Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by 5 National Cancer Institute-sponsored cooperative groups. J Clin Oncol. 2007; 25: 1272-1276.
  • 48
    Lai GY,Gary TL,Tilburt J, et al. Effectiveness of strategies to recruit underrepresented populations into cancer clinical trials. Clin Trials. 2006; 3: 133-141.
  • 49
    Lewis JH,Kilgore ML,Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003; 21: 1383-1389.
  • 50
    Townsley CA,Selby R,Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol. 2005; 23: 3112-3124.
View Full Article (HTML) Get PDF (344K)